logo

For the Inventor, By the Inventor

Osaka, Japan

Kringle Pharma Inc.


USPTO Granted Patents = 14

% Expired Patents = 57.1



Trademarks = 3

Forward Citations = 23

Loading Chart...
Loading Chart...

28 inventors (with patents filed for the assignee):

goldMedal Toshikazu Nakamura (10 out of 37 patents)

silverMedal Kunio Matsumoto (8 out of 11 patents)

bronzeMedal Kazuhiro Fukuta (5 out of 7 patents)

4.  Jun Amano (3 out of 7 patents)

5.  Keigo Hanada (3 out of 3 patents)

6.  Ken-ichi Ito (3 out of 3 patents)

7.  Kazuhiro Yamaura (3 out of 3 patents)

8.  Kiichi Adachi (3 out of 3 patents)

9.  Hayao Inoue (2 out of 4 patents)

10.  Hiroshi Funakoshi (2 out of 2 patents)

11.  Daichika Hayata (2 out of 2 patents)

12.  Hideyuki Okano (1 out of 30 patents)

13.  Arihiko Kanehiro (1 out of 5 patents)

14.  Hiroyuki Tsuchiya (1 out of 7 patents)

15.  Yoshiaki Toyama (1 out of 5 patents)


14 patents:

1. 10702582 - HGF preparation suitable for treatment of neurological disorders (2020-07-07),
2. 10213485 - HGF preparation suitable for treatment of neurological disorders (2019-02-26),
3. 8927493 - Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue (2015-01-06),
4. 8575099 - Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof (2013-11-05),
5. 8518880 - Therapeutic agent for spinal cord injuries (2013-08-27),
6. 8461112 - HGF preparation (2013-06-11),
7. 8383588 - Fibrosis inhibitor for implanted organ (2013-02-26),
8. 8278270 - HGF precursor protein variant and active protein thereof (2012-10-02),
9. 8076289 - Fibrosis inhibitor for implanted organ (2011-12-13),
10. 8003607 - HGF precursor protein variant and active protein thereof (2011-08-23),
11. 7838494 - Differentiation- or regeneration-inducing agent for alveoli (2010-11-23),
12. 7807177 - Segment of glycosylation-deficient HGFalpha-chain (2010-10-05),
13. 7696170 - Fibrosis inhibitor for implanted organ (2010-04-13),
14. 7563768 - Asthma preparation (2009-07-21),
Company Overview
Kringle Pharma Inc. is a biopharmaceutical company based in Osaka, Japan, focused on the development of innovative therapies for rare diseases. The organization specializes in protein engineering and drug formulation, leveraging advanced biotechnological methods to create effective treatments. With a commitment to addressing unmet medical needs, Kringle Pharma aims to improve patient outcomes through its research in therapeutic proteins and novel delivery systems, contributing to the global healthcare landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

14 Patents

#386 in Osaka

#3,580 in Japan

#42,249 in the World

Osaka, JP
Osaka, Japan

Kringle Pharma Inc.

Forward Citations = 23

28 inventors:

goldMedal Toshikazu Nakamura (10 out of 37 patents)

silverMedal Kunio Matsumoto (8 out of 11 patents)

bronzeMedal Kazuhiro Fukuta (5 out of 7 patents)

4.  Jun Amano (3 out of 7 patents)

5.  Keigo Hanada (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Kringle Pharma Inc.. Retrieved from https://idiyas.com/company/kringle-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…